Investors > Investor Information

Webcast - Replay Jefferies 2nd Annual Healthcare Conference 06/26/08 at 11:15 a.m. ET

Webcast - Replay Vivus Investor Luncheon 06/10/08 at 11:30 a.m. PT

Webcast - Replay Vivus at Canaccord Adams Diabetes & Obesity Conference 06/06/08 at 12:20 p.m. PT

VVUS (Common Stock) Exchange NASDAQ Price $7.49 Change (%)   0.17 (2.32%) Volume 493,986 Data as of 07/03/08 1:00 p.m. ET Minimum 20 minute delay Refresh quote

Corporate Profile

VIVUS, Inc. is a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products addressing obesity and sexual health. The investigational pipeline includes: Qnexa™, which is in Phase 3 for the treatment of obesity and Phase 2 for the treatment of diabetes; Testosterone MDTS®, for which a Phase 2 study has been completed for the treatment of Hypoactive Sexual Desire Disorder (HSDD); and avanafil, for which a Phase 2 study has been completed for the treatment of erectile dysfunction (ED). MUSE® is approved and currently on the market for the treatment of ED. For more information on clinical trials and products, please visit the company's web site at www.vivus.com.

Recent News

More >>

06-26-08 VIVUS Announces New Data from Qnexa Diabetes Study 06-20-08 VIVUS to Present at the Jefferies 2nd Annual Healthcare Conference 06-13-08 VIVUS Announces Presentation of Qnexa Data at the 2008 BIO International Convention 06-10-08 Qnexa Reduces Hemoglobin A1c by 1.2 Percent in 28 Weeks

Upcoming Events

More >>

There are currently no events scheduled.

Receive E-mail Alerts

Sign up to receive e-mail alerts whenever Vivus posts new information to the site. Just enter your e-mail address and click Submit.